Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.03 is 13% below its 4-year average of 0.03, around the middle of its 4-year range (-0.12–0.24).
As of the fiscal period ended Tuesday, June 30, 2026. 36.24% below its 12-month average of 0.05.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.03.
DEBT TO EQUITY RATIO
0.03
DEBT TO EQUITY RATIO AVG TTM
0.05
DEBT TO EQUITY RATIO AVG 3Y
0.07
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-36.24%
CURRENT VS 3Y AVG
-55.93%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 529 covered companies
CURRENT VS SECTOR MEDIAN
-77.71%
vs the sector median at left
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$250.09M
Debt to Equity Ratio
0.03
TTM Avg
0.05
3Y Avg
0.07
5Y Avg
N/A
Market Cap
$255.42M
Debt to Equity Ratio
0.15
TTM Avg
0.30
3Y Avg
0.26
5Y Avg
0.22
Market Cap
$244.47M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$255.89M
Debt to Equity Ratio
0.17
TTM Avg
0.17
3Y Avg
0.15
5Y Avg
0.12
Market Cap
$243.91M
Debt to Equity Ratio
9.64
TTM Avg
54.87
3Y Avg
37.52
5Y Avg
22.91
Market Cap
$242.25M
Debt to Equity Ratio
N/A
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
1.23
Market Cap
$259.91M
Debt to Equity Ratio
0.13
TTM Avg
0.07
3Y Avg
0.16
5Y Avg
0.51
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $250.09M | 0.03 | 0.05 | 0.07 | N/A |
| Invivyd, Inc. (IVVD)vs › | $246.20M | 0.05 | 0.01 | 0.01 | 0.01 |
| Century Therapeutics, Inc. (IPSC)vs › | $255.42M | 0.15 | 0.30 | 0.26 | 0.22 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $244.47M | 0.00 | 0.00 | 0.00 | 0.00 |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.89M | 0.17 | 0.17 | 0.15 | 0.12 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.91M | 9.64 | 54.87 | 37.52 | 22.91 |
| AC Immune S.A. (ACIU)vs › | $256.98M | 0.12 | 0.08 | 0.05 | 0.04 |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.25M | N/A | 0.09 | 0.09 | 1.23 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $259.91M | 0.13 | 0.07 | 0.16 | 0.51 |
| InflaRx N.V. (IFRX)vs › | $240.09M | 0.01 | 0.01 | 0.01 | 0.01 |
Debt/Equity
0.03
Current Ratio
13.89
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.03 |
| 2026-03-31 | 0.03 |
| 2025-12-31 | 0.03 |
| 2025-09-30 | 0.07 |
| 2025-06-30 | 0.06 |
| 2025-03-31 | 0.11 |
| 2024-12-31 | 0.08 |
| 2024-09-30 | 0.07 |
| 2024-06-30 | 0.07 |
| 2024-03-31 | 0.06 |
| 2023-12-31 | 0.10 |
| 2023-09-30 | -0.10 |
| 2023-06-30 | -0.09 |
| 2023-03-31 | 0.24 |
| 2022-12-31 | -0.12 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
